Can a Brain-Penetrating drug tackle recurrent CNS lymphoma?

NCT ID NCT04906096

Recruiting now Disease control Sponsor: Lakshmi Nayak, MD Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether paxalisib (GDC-0084), an oral drug taken daily, can shrink or control tumors in people with recurrent or refractory primary central nervous system lymphoma (PCNSL) — a rare type of non-Hodgkin lymphoma that starts in the brain or spinal cord. The study will measure how many participants achieve a complete or partial response, and whether those responses last at least six months. Participants will take paxalisib in 28-day cycles for up to 24 months, with regular monitoring for safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paxalisib (GDC-0084), an oral drug taken daily
What this could lead to: If paxalisib shows meaningful and durable responses, it could offer a new treatment option for people with recurrent or refractory primary CNS lymphoma, a challenging cancer of the brain or spinal cord.
What could go wrong: This is a small phase 2 study, so results may not confirm effectiveness. The drug may cause side effects, and not all participants may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA OF EXTRANODAL SITE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA OF EXTRANODAL SITE PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.